Targeting Upstream Mediators and the Airway Epithelium With Next-Generation Biologics
Targeting Upstream Mediators and the Airway Epithelium With Next-Generation Biologics is organized by Integrity Continuing Education Inc..
Release date: 29- 07- 2022
Expiration date: 29-07- 2023
Program Overview:
This interactive activity will provide relevant clinicians with a greater understanding of the unmet needs in severe asthma, the alarmin pathway, and novel biologic therapies and their potential positioning within the therapeutic landscape. This may lead to improved treatment practices and better outcomes for the broader severe asthma population.
After a brief lecture, learners will enter the virtual interactive exam room where they’ll have an opportunity to work through two standardized clinical cases.
Learning Objectives:
Upon completion of this educational activity, participants should be able to:
• Describe the unmet needs with current severe asthma therapies and the contributions of the airway epithelium and hyperresponsiveness in the disease
• Explain the involvement of alarmins in severe asthma and the rationale for targeting upstream cytokines in controlling the disease
• Apply newly approved treatments that address the alarmin pathway in severe asthma in appropriate patient types
Additional details will be posted as soon as information is available.